Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -5.97% | +1.07% | -80.73% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
- The company appears to be poorly valued given its net asset value.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-80.73% | 547M | C | ||
+9.55% | 222B | B | ||
+14.41% | 195B | B- | ||
+24.02% | 148B | B- | ||
+33.92% | 113B | A- | ||
+4.18% | 66.45B | A- | ||
+12.92% | 53.11B | B+ | ||
+3.16% | 50.03B | B+ | ||
-4.32% | 38.8B | A | ||
-1.99% | 34.85B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PACB Stock
- Ratings Pacific Biosciences of California, Inc.